A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II). - Barbanti P; Aurilia C; Egeo G; Doretti A; d'Onofrio F; Scatena P; Rinalduzzi S; Vinciguerra L; Sansone M; Vecchio R; Drago V; Viticchi G; et al. (Journal of neurology, 2025)